Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial
The Lancet Neurology,  Clinical Article

Hankey GJ et al. – The findings support the hypothesis that antiplatelet therapy modifies the potential benefits of lowering homocysteine with B–vitamin supplementation in the secondary prevention of major vascular events. If validated, B vitamins might have a role in the prevention of ischaemic events in high–risk individuals with an allergy, intolerance, or lack of indication for antiplatelet therapy.

Methods
  • In the VITATOPS trial, 8164 patients with recent stroke or transient ischaemic attack were randomly allocated to double–blind treatment with one tablet daily of placebo or B vitamins (2 mg folic acid, 25 mg vitamin B6, and 500 μg vitamin B12) and followed up for a median 3•4 years (IQR 2•0—5•5) for the primary composite outcome of stroke, myocardial infarction, or death from vascular causes.
  • In the post–hoc analysis of the interaction between antiplatelet therapy and the effects of treatment with B vitamins on the primary outcome, the authors used Cox proportional hazards regression before and after adjusting for imbalances in baseline prognostic factors in participants who were and were not taking antiplatelet drugs at baseline and in participants assigned to receive B vitamins or placebo.
  • The authors also assessed the interaction in different subgroups of patients and different secondary outcomes.
  • At baseline, 6609 patients were taking antiplatelet therapy and 1463 were not.

Results
  • Patients not receiving antiplatelet therapy were more likely to be younger, east Asian, and disabled, to have a haemorrhagic stroke or cardioembolic ischaemic stroke, and to have a history of hypertension or atrial fibrillation.
  • They were less likely to be smokers and to have a history of peripheral artery disease, hypercholesterolaemia, diabetes, ischaemic heart disease, and a revascularisation procedure.
  • Of the participants taking antiplatelet drugs at baseline, B vitamins had no significant effect on the primary outcome (488 patients in the B–vitamins group [15%] vs 519 in the placebo group [16%]; hazard ratio [HR] 0.94, 95% CI 0.83—1.07).
  • By contrast, of the participants not taking antiplatelet drugs at baseline, B vitamins had a significant effect on the primary outcome (123 in the B–vitamins group [17%] vs 153 in the placebo group [21%]; HR 0.76, 0.60—0.96).
  • The interaction between antiplatelet therapy and the effect of B vitamins on the primary outcome was significant after adjusting for imbalance in the baseline variables (adjusted p for interaction=0.0204).

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Cardiology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Cardiology Articles

1 Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials Hypertension, September 29, 2014    Evidence Based Medicine    Review Article

2 Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation European Heart Journal, September 16, 2014    Clinical Article

3 Effects of tea intake on blood pressure: A meta-analysis of 21 randomized controlled trials JACC - Journal of the American College of Cardiology, October 22, 2014    Clinical Article

4 Chemicals found in everyday fruits could minimise organ damage after heart attack and stroke University of Cambridge News, November 14, 2014

5 PCI versus CABG: a meta-analysis The Journal of Thoracic and Cardiovascular Surgery, November 13, 2014    Clinical Article

6 Statins and almonds to lower lipoproteins (the STALL study) Journal of Clinical Lipidology, November 17, 2014

7 ‘Big data’ approach helps pinpoint possible new stent drug to prevent heart attacks Stanford School of Medicine News, November 20, 2014

8 What the guidelines do not say: statin non-benefit groups Current Atherosclerosis Reports, November 20, 2014    Clinical Guideline    Clinical Article

9 Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure Hypertension, November 25, 2014    Clinical Article

10 Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation International Journal of Cardiology, November 26, 2014    Clinical Article

11 Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT Journal of the American Society of Hypertension, November 4, 2014    Clinical Article

12 Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy EP Europace, September 19, 2014    Clinical Article

13 Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents New England Journal of Medicine, November 19, 2014    Evidence Based Medicine    Clinical Article

14 Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: A meta-analysis Vascular Pharmacology, November 12, 2014    Clinical Article

15 The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: Results of a randomized trial American Heart Journal, October 1, 2014    Clinical Article

16 Meta-analysis on risk of bleeding with apixaban in patients with renal impairment The American Journal of Cardiology, November 21, 2014    Evidence Based Medicine    Review Article    Clinical Article

17 Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial Full Text Trials, November 18, 2014    Free full text    Evidence Based Medicine    Clinical Article

18 Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individuals International Journal of Cardiology, November 7, 2014    Clinical Article

19 Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: A systematic review and meta-analysis of randomised clinical trials European Journal of Preventive Cardiology, November 26, 2014    Evidence Based Medicine    Review Article

20 A systematic review of statin-induced muscle problems in clinical trials American Heart Journal, October 7, 2014    Review Article

Indexed Journals in Cardiology: American Heart Journal, American Journal of Cardiology, Circulationn, Heartmore